<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="2" ids="35475">Nonsteroidal anti-inflammatory drugs</z:chebi> (<z:chebi fb="1" ids="35475">NSAIDs</z:chebi>) have been widely reported to inhibit <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> by a COX-independent mechanism, although alternative targets have not been well defined or used to develop improved drugs for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> chemoprevention </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we characterize a novel <z:chebi fb="0" ids="9352">sulindac</z:chebi> derivative referred to as <z:chebi fb="0" ids="9352">sulindac</z:chebi> <z:chebi fb="0" ids="40538">benzylamine</z:chebi> (SBA) that does not inhibit COX-1 or COX-2, yet potently inhibits the growth and induces the <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of human <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumor</z:e> cells </plain></SENT>
<SENT sid="2" pm="."><plain>The basis for this activity appears to involve cyclic <z:chebi fb="0" ids="16750">guanosine</z:chebi> 3',5',-monophosphate phosphodiesterase (cGMP PDE) inhibition as evident by its ability to inhibit cGMP hydrolysis in <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumor</z:e> cell lysates and purified cGMP-specific PDE5, increase intracellular cGMP levels, and activate cGMP-dependent protein kinase G at concentrations that suppress <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell growth </plain></SENT>
<SENT sid="3" pm="."><plain>PDE5 was found to be essential for <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumor</z:e> cell growth as determined by siRNA knockdown studies, elevated in <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumor</z:e> cells as compared with <z:mpath ids='MPATH_458'>normal</z:mpath> colonocytes, and associated with the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> selectivity of SBA </plain></SENT>
<SENT sid="4" pm="."><plain>SBA activation of PKG may suppress the oncogenic activity of β-catenin as evident by its ability to reduce β-catenin nuclear levels, Tcf (T-cell factor) transcriptional activity, and survivin levels </plain></SENT>
<SENT sid="5" pm="."><plain>These events preceded <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induction and appear to result from a rapid elevation of intracellular cGMP levels following cGMP PDE inhibition </plain></SENT>
<SENT sid="6" pm="."><plain>We conclude that PDE5 and possibly other cGMP degrading isozymes can be targeted to develop safer and more efficacious <z:chebi fb="1" ids="35475">NSAID</z:chebi> derivatives for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> chemoprevention </plain></SENT>
</text></document>